Feb 17 (Reuters) - Cytokinetics Inc CYTK.O:
CYTOKINETICS ANNOUNCES EUROPEAN COMMISSION APPROVAL OF MYQORZO® (AFICAMTEN) FOR THE TREATMENT OF ADULTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
CYTOKINETICS INC: FIRST EUROPEAN LAUNCH EXPECTED IN GERMANY IN Q2 2026
Source text: ID:nGNXbhJ25h
Further company coverage: CYTK.O
((Reuters.Briefs@thomsonreuters.com;))